Pharmaceuticals · 2023 · 10 citations · 26 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryHypoxia AdaptationMulti-target Drug DesignOncology PharmacologyBiological Evaluation ReportDual-target InhibitorsHypoxia ModulationHypoxia-dependent GrowthHypoxia-inducible Factor RegulationHypoxia-inducible Factor SignalingHypoxia-mediated Resistance
MDH1 and MDH2 enzymes play an important role in the survival of lung cancer. In this study, a novel series of dual MDH1/2 inhibitors for lung cancer was rationally designed and synthesized, and their SAR was carefully investigated. Among the tested compounds, compound 50 containing a piperidine ring displayed an improved growth inhibition of A549 and H460 lung cancer cell lines compared with LW1497. Compound 50 reduced the total ATP content in A549 cells in a dose-dependent manner; it also significantly suppressed the accumulation of hypoxia-inducible factor 1-alpha (HIF-1α) and the expression of HIF-1α target genes such as GLUT1 and pyruvate dehydrogenase kinase 1 (PDK1) in a dose-dependent manner. Furthermore, compound 50 inhibited HIF-1α-regulated CD73 expression under hypoxia in A549 lung cancer cells. Collectively, these results indicate that compound 50 may pave the way for the development of next-generation dual MDH1/2 inhibitors to target lung cancer.
26
Hallmarks of Cancer: New Dimensions
Cancer Discovery · 2022 · 9.1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying, Alec C. Kimmelman, Costas A. Lyssiotis et al. · Cell · 2012 · 2K citations · Full text
Medicine, Cancer Biology, Oncology +11
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son, Costas A. Lyssiotis, Haoqiang Ying et al. · Nature · 2013 · 2K citations · Full text
Medicine, Cancer Biology, Oncology +12